Objective To observe the clinical effect of combination therapy of Butylphthalide and Sodium Chloride injection,Naoxintong and Sodium Tanshinone ⅡA Sulfate in acute ischemic stroke patients. Methods 231 patients with acute ischemic stroke were retrospectively ana-lyzed. 130 cases of control group patients were treated with NBP injection (100 ml/ d),and the other 101 cases of observation group patients were treated with NBP injection (100 ml/ d,i. v. ),Naoxintong (0. 8 ～ 1. 6 g/ d,p. o. )combined with sodium tanshinone ⅡA sulfate (40 ～ 80 mg/d,i. v. ). The clinical therapeutic efficiency,the serum levels of inflammatory factors (IL - 6,TNF - α and hs - CRP),disability rate,relapse rate and death rate were compared between the two groups. Results According to the test results,the serum levels of inflammatory factors (IL -6,TNF - α and hs - CRP),NIHSS scores and mRS scores of patients in the observation group were all lower than those of the control group;es-pecially the level of hs - CRP (5. 92 ± 2. 01mg/ L)was obviously lower than that of the control group (10. 07 ± 1. 99 mg/ L)after 14d treatment. And the difference was statistically significant (P 0. 05). Conclusion The butylphthalide and sodium chloride,Naoxintong combined with sodium tanshinone ⅡA sulfate in treatment of acute ischemic stroke is effective and safe,which can obviously reduce the serum lev-els of inflammatory factors (IL - 6,TNF - α and hs - CRP). Therefore,it is recommended for the clinical application.%目的 观察并探讨丁苯酞氯化钠、脑心通胶囊联合丹参酮ⅡA磺酸钠治疗急性缺血性脑卒中患者的临床疗效和安全性.方法 回顾性分析231例急性缺血性脑卒中患者的临床资料,其中对照组130例患者接受丁苯酞氯化钠(100 ml/d)静脉滴注治疗,观察组101例患者接受丁苯酞氯化钠(100 ml/d,静脉滴注)、脑心通胶囊(0.8～1.6 g/次,口服,每日三次)联合丹参酮ⅡA磺酸钠(40～80 mg/d,静脉滴注)治疗.比较两组患者的临床疗效、血清中炎性因子[白介素-6(IL-6),肿瘤坏死因子-α(TNF-α),超敏C反应蛋白(hs-CRP)]水平的变化、致残率、复发率以及病死率.结果 经治疗后,观察组患者血清中炎性因子(IL-6,TNF-α,hs-CRP)水平、NIHSS评分和mRS评分明显均低于对照组(P0.05).结论 丁苯酞氯化钠、脑心通胶囊联合丹参酮ⅡA磺酸钠治疗急性缺血性脑卒中,可显著降低患者血清中炎性因子含量水平,疗效显著,安全性良好,致残率较低,可作为临床推荐治疗方案.
展开▼
